CM 1 ~~40.~~ A compound of the formula

T 1100X



Ib

CMS wherein Ra is nitro or cyano, Rb is hydrogen or halogen, Rc' is the group CO-R^{11} wherein R^{11} is a phenyl group optionally mono- or disubstituted by halogen, cyano, hydroxy or lower alkyl, or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof.

13

Claim 2, line 1: please change "Claim 1" to --- Claim 40 ---.

Claim 8, line 1: please change "Claim 1" to --- Claim 40 ---.

Claim 9, line 1: please change "Claim 1" to --- Claim 40 ---.

Please cancel Claim 10.

Please cancel claim 11 and replace with new Claim 41.

110

8 42. A pharmaceutical composition comprising a compound of the formula

T1130X



C2
PS

wherein Ra is nitro or cyano, Rb is hydrogen or halogen, Rc is CO-R^1 wherein R^1 is a phenyl group optionally mono- or
13
disubstituted by halogen, cyano, hydroxy or lower alkyl or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.

Claim 12, line 2: please change "11" to --- 41 ---.

Claim 13, line 2: please change "11" to --- 41 ---.

Please cancel Claim 14.

Please cancel Claim 15 and replace with new Claim 42.

113

42. A pharmaceutical composition comprising L-dopa, peripheral decarboxylase inhibitor, a compound of the formula



wherein Ra is nitro or cyano, Rb is hydrogen or halogen, Rc is the group CO-R^1 wherein R^1 is a phenyl group optionally mono- or disubstituted by halogen, cyano, hydroxy or lower alkyl or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier material.

Claim 16, line 2: please change "15" to --- 42 ---.

Claim 17, line 15: please change "15" to --- 42 ---.

Please cancel Claims 18-30.

Claim 31, line 1: please change "Claim 1" to --- Claim 40 ---.

Claim 32, line 1: please change "Claim 11" to --- Claim 41 ---.

Claim 33, line 1: please change "Claim 15" to --- Claim 42 ---.

Please cancel Claim 34 and replace with new Claim 43.

43. 17 A pharmaceutical composition for treating depression comprising an effective amount of a compound of the formula



Ia

CY

wherein Ra is nitro or cyano, Rb is hydrogen or halogen, Rc is CO-R^1 wherein R^1 is a phenyl group optionally mono- or disubstituted by halogen, cyano, hydroxy or lower alkyl or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.

Claim 35, line 1: please change "Claim 34" to --- Claim 43 ---.

Please cancel Claim 36 and replace with new Claim 44.

~~44.~~ 19 A pharmaceutical composition for treating Parkinson's disease comprising L-dopa, a peripheral decarboxylase inhibitor, a compound of the formula



Ia

C5

wherein Ra is nitro or cyano, Rb is hydrogen or halogen, Rc is CO-R^1 wherein R^1 is a phenyl group optionally mono- or disubstituted by halogen, cyano, hydroxy or lower alkyl or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.

Claim ~~37~~, line 1: please change "Claim 36" to --- Claim 44 ---.

Please cancel Claim 38 and replace with new Claim 45.

~~45.~~ 21/ A pharmaceutical composition for inhibiting catechol-O-methyl-transferase, said composition comprising a catechol-O-methyl-transferase inhibiting amount of a compound of the formula



Ia

C5

wherein Ra is nitro or cyano, Rb is hydrogen or halogen, Rc is CO-R^1 wherein R^1 is a phenyl group optionally mono- or disubstituted by halogen, cyano, hydroxy or lower alkyl, or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.

Claim 39, line 1: please change "Claim 38" to --- Claim 45 ---.

REMARKS

Reconsideration of the captioned application in view of the foregoing amendments and the remarks which follow is courteously requested.